361 related articles for article (PubMed ID: 11197882)
1. [The effect of suplatast tosilate on immunological parameters for the patients with atopic dermatitis].
Suto H; Mitsuishi K; Hira K; Uchida T; Unno T; Ogawa H; Yoshiike T; Takamori K
Arerugi; 2000 Dec; 49(12):1163-72. PubMed ID: 11197882
[TBL] [Abstract][Full Text] [Related]
2. [The effect of suplatast tosilate on the patients with atopic dermatitis--relationship between clinical symptoms and immunological parameters].
Higashi N; Niimi Y; Aoki M; Fujimoto K; Suzuki K; Numano K; Kawana S
Arerugi; 2003 Nov; 52(11):1065-73. PubMed ID: 14685038
[TBL] [Abstract][Full Text] [Related]
3. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate.
Kimata H
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):293-5. PubMed ID: 10094221
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of suplatast tosilate, a Th2 cytokine inhibitor based on the Th1/Th2 ratio for allergic disease in children: a retrospective study.
Yoshihara S; Fukuda H; Arisaka O
Arzneimittelforschung; 2011; 61(7):421-4. PubMed ID: 21899211
[TBL] [Abstract][Full Text] [Related]
5. Early intervention with suplatast tosilate for prophylaxis of pediatric atopic asthma: a pilot study.
Yoshihara S; Ono M; Yamada Y; Fukuda H; Abe T; Arisaka O
Pediatr Allergy Immunol; 2009 Aug; 20(5):486-92. PubMed ID: 19210644
[TBL] [Abstract][Full Text] [Related]
6. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5.
Murakami T; Yamanaka K; Tokime K; Kurokawa I; Tsutsui H; Nakanishi K; Mizutani H
Br J Dermatol; 2006 Jul; 155(1):27-32. PubMed ID: 16792748
[TBL] [Abstract][Full Text] [Related]
7. Effect of an orally active Th2 cytokine inhibitor, suplatast on "atopic cough" tosilate.
Ishiura Y; Fujimura M; Yamamoto H; Nobata K; Ishiguro T; Ogawa H; Myou S
Arzneimittelforschung; 2008; 58(6):297-302. PubMed ID: 18677972
[TBL] [Abstract][Full Text] [Related]
8. Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis.
Washio Y; Ohashi Y; Tanaka A; Kakinoki Y; Sugiura Y; Sakamoto H; Yamada K; Matsuda M; Uekawa M; Okamoto H; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():126-32. PubMed ID: 9879412
[TBL] [Abstract][Full Text] [Related]
9. [Peripheral eosinophil counts relates the improvement of the skin lesions of atopic dermatitis patients more sensitive than serum eosinophil cationic protein levels].
Nishimoto M; Numahara T; Nakashima K; Yoshida T
Arerugi; 1998 Jun; 47(6):591-6. PubMed ID: 9721450
[TBL] [Abstract][Full Text] [Related]
10. Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness.
Horiguchi T; Tachikawa S; Handa M; Hanazono K; Kondo R; Ishibashi A; Banno K
J Asthma; 2001 Jun; 38(4):331-6. PubMed ID: 11456386
[TBL] [Abstract][Full Text] [Related]
11. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
[TBL] [Abstract][Full Text] [Related]
12. Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients.
Yoshida M; Aizawa H; Inoue H; Matsumoto K; Koto H; Komori M; Fukuyama S; Okamoto M; Hara N
J Asthma; 2002 Sep; 39(6):545-52. PubMed ID: 12375715
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables.
Park JH; Choi YL; Namkung JH; Kim WS; Lee JH; Park HJ; Lee ES; Yang JM
Br J Dermatol; 2006 Oct; 155(4):778-83. PubMed ID: 16965428
[TBL] [Abstract][Full Text] [Related]
14. Significance of the eosinophil cationic protein/eosinophil count ratio in asthmatic patients: its relationship to disease severity.
Fujitaka M; Kawaguchi H; Kato Y; Sakura N; Ueda K; Abe Y
Ann Allergy Asthma Immunol; 2001 Mar; 86(3):323-9. PubMed ID: 11289333
[TBL] [Abstract][Full Text] [Related]
15. Eosinophil involvement in rheumatoid arthritis as reflected by elevated serum levels of eosinophil cationic protein.
Hällgren R; Feltelius N; Svenson K; Venge P
Clin Exp Immunol; 1985 Mar; 59(3):539-46. PubMed ID: 3987090
[TBL] [Abstract][Full Text] [Related]
16. [Cytokine production by peripheral blood mononuclear cells in bronchial asthma treated with suplatast tosilate].
Yamasawa H; Oshikawa K; Sugiyama Y
Arerugi; 2001 Jun; 50(6):513-9. PubMed ID: 11517513
[TBL] [Abstract][Full Text] [Related]
17. Suplatast tosilate alters DC1/DC2 balance in peripheral blood in bronchial asthma.
Yokomura K; Suda T; Matsuda H; Hashizume H; Asada K; Suzuki K; Chida K
J Asthma; 2005 Sep; 42(7):567-70. PubMed ID: 16169790
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults.
Capella GL; Grigerio E; Altomare G
Eur J Dermatol; 2001; 11(3):209-13. PubMed ID: 11358726
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitory effect of suplatast tosilate on eosinophil migration].
Kobayashi Y; Nagata M; Yamamoto H; Sakamoto Y
Arerugi; 2000 Jul; 49(7):600-3. PubMed ID: 10944827
[TBL] [Abstract][Full Text] [Related]
20. Suplatast/tacrolimus combination therapy for refractory facial erythema in adult patients with atopic dermatitis: a meta-analysis study.
Miyachi Y; Katayama I; Furue M
Allergol Int; 2007 Sep; 56(3):269-75. PubMed ID: 17582208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
